| ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA |
| Adverse effects of COVID-19 vaccines and measures to prevent them |
| Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines |
| Alternate mechanisms of mRNA vaccine toxicity: which one is the main culprit? |
| Anti-recoverin Antibody-Associated Post-acute COVID Vaccination Syndrome After BNT162b2 in HLA-B27-Positive Spondylarthritis: A Case Report |
| Antiviral treatments [Molnupiravir] lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients |
| Autoimmune and Neoplastic Outcomes After the mRNA Vaccination: The Role of T Regulatory Cell Responses |
| BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists |
| Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 - A Multidisciplinary Perspective |
| Class switch toward noninflammatory, spike-specificIgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination |
| Comirnaty Facts: Mechanisms of action and damage potential |
| Commentary from Dr. David Bauer of the Francis Crick Institute |
| Compilation: Peer Reviewed Medical Papers of COVID Vaccine Injuries |
| Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1 |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2 |
| COVID-19 vaccines – An Australian Review |
| Excitotoxicity (Immunoexcitotoxicity) as a Critical Component of the Cytokine Storm Reaction in Pulmonary Viral Infections, Including SARS-Cov-2 |
| Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice |
| Hemophagocytic Lymphohistiocytosis (HLH) Flare Following the COVID-19 Vaccine: A Case Report |
| Homology between SARS CoV-2 and human proteins |
| Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
| Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs |
| Metastatic prostatic adenocarcinoma presenting as generalized lymphadenopathy unmasked by a COVID booster vaccine |
| mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review |
| mRNA Vaccine Toxicity |
| National Academies Committee on Review of Relevant Literature Regarding Adverse Events Associated with Vaccines March 30 2023: Written material accompanying oral remarks |
| Need for validation of vaccination programs |
| New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review |
| Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination |
| Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV viruses |
| Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms |
| Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry |
| SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly |
| Strategies for the Management of Spike Protein-Related Pathology |
| The COVID-19 “Vaccines”: What is the truth? |
| Toxic Shot: Facing the Dangers of the COVID “Vaccines” |
| Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam |
| Turbo Cancer after Covid Injections |
| Urgent Open Letter from Doctors and Scientists to the European Medicines Agency regarding COVID-19 Vaccine Safety Concerns |
| Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation |
